Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
| Filed | Insider | Role | Shares | Value | |
|---|---|---|---|---|---|
| 2026-11-10 | SCULLY WILLIAM P | 10%-owner | 140,000 | $1,194,158 | Form 4 |
| 2026-10-26 | SCULLY WILLIAM P | 10%-owner | 150,000 | $1,222,045 | Form 4 |
| 2026-10-15 | SCULLY WILLIAM P | 10%-owner | 110,000 | $920,049 | Form 4 |
| 2026-10-09 | SCULLY WILLIAM P | 10%-owner | 215,000 | $1,821,054 | Form 4 |
| 2026-10-06 | SCULLY WILLIAM P | 10%-owner | 100,000 | $857,240 | Form 4 |
| 2026-09-30 | SCULLY WILLIAM P | 10%-owner | 162,000 | $1,405,674 | Form 4 |
| 2026-09-29 | SCULLY WILLIAM P | 10%-owner | 103,500 | $889,872 | Form 4 |
| 2026-09-21 | SCULLY WILLIAM P | 10%-owner | 100,000 | $843,460 | Form 4 |
| 2026-09-03 | SCULLY WILLIAM P | 10%-owner | 27,000 | $255,739 | Form 4 |
| 2026-08-21 | SCULLY WILLIAM P | 10%-owner | 50,000 | $439,430 | Form 4 |
| 2026-08-10 | SCULLY WILLIAM P | 10%-owner | 37,500 | $323,220 | Form 4 |
| 2026-05-26 | SCULLY WILLIAM P | 10%-owner | 100,000 | $981,300 | Form 4 |
from2028 — cross-site stock view. Rebuilt at publish time.